Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05662215 · ClinicalTrials.gov registry record · Phase 1
A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants
A Phase 1 study, sponsored by Cytokinetics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
NCT05662215: Clinical Trial Phase 1 study, sponsored by Cytokinetics.
NCT05662215 is a Phase 1 study that was terminated before completion, run by Cytokinetics. The registered enrollment target is 57 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05662215, a Phase 1 study, was terminated before completion, sponsored by Cytokinetics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
Study Summary
1. Learn about the safety and tolerability of CK-3828136 after a single dose and multiple doses in healthy subjects. 2. Find out how much CK-3828136 is in the blood after a single dose and multiple doses. 3. Determine the effect different doses of CK-3828136 on the pumping function of the heart.
Primary Outcome
To assess the safety and tolerability of CK-3828136 when administered orally as single or multiple doses to healthy participants
Interventions
- DRUG CK-3828136
- DRUG Placebo for CK-3828136
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2022-12-06 |
| Est. Completion | 2023-08-08 |
| Phase | Phase 1 |
Why NCT05662215 stopped before completion
NCT05662215 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which CK-3828136 is the first listed.
NCT05662215 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05662215 about?
NCT05662215 is a clinical study titled "A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants". 1. Learn about the safety and tolerability of CK-3828136 after a single dose and multiple doses in healthy subjects. 2. Find out how much CK-3828136 is in the blood after a single dose and multiple doses. 3. Determine the effect different doses of CK-3828136 on the pumping function of the heart.
What is the current status of trial NCT05662215?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2022-12-06. Estimated completion is 2023-08-08.
What interventions are being tested in trial NCT05662215?
The interventions under investigation include: CK-3828136 (DRUG), Placebo for CK-3828136 (DRUG).
Who is sponsoring clinical trial NCT05662215?
This trial is sponsored by Cytokinetics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05662215's enrollment target sits among peer trials
57 901st of 2000 higher than 1,099 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI